Trial Profile
A Phase III, Multicenter, Open-Label Randomized Trial Comparing the Efficacy of GA101 (RO5072759) in Combination With CHOP (G-CHOP) Versus Rituximab and CHOP (R-CHOP) in Previously Untreated Patients With CD20-Positive Diffuse Large B-Cell Lymphoma (DLBCL)
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 29 Jan 2024
Price :
$35
*
At a glance
- Drugs Obinutuzumab (Primary) ; Cyclophosphamide; Doxorubicin; Prednisolone; Rituximab; Vincristine
- Indications Diffuse large B cell lymphoma
- Focus Registrational; Therapeutic Use
- Acronyms GOYA
- Sponsors Chugai; Nippon Shinyaku; Roche
- 12 Dec 2023 Results assessing Molecular Determinants of Response to Mosunetuzumab Plus (R-CHOP) NCT01287741 and M-CHOP in NCT03677141 , in Patients with Diffuse Large B Cell Lymphoma , presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 09 Nov 2022 Results assessing Cost-Effectiveness and Cost-Utility Analyses of Polatuzumab Vedotin With Rituximab and Chemotherapy vs Rituximab and Chemotherapy in Treating Naive Diffuse Large B-Cell Lymphoma in Italy presented at the 25th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research
- 01 Aug 2022 Data from this study assessing baseline total metabolic tumor volume is prognostic for refractoriness to Immunochemotherapy in DLBCL published in the Clinical Lymphoma, Myeloma & Leukemia